Monopar Therapeutics Inc. Insider Trading

MNPR

Last 12 months

Insiders bought 105K and sold $4.87M on the open market.

93% of the selling was scheduled in advance under 10b5-1 plans. Director Arthur J Klausner sold 344K on Dec 18, 2025, 37% of their stake, outside a plan.

Net open-market

−$4.77M

1 buy · 7 sales

Under a 10b5-1 plan

93%

of the value sold

Insiders who bought / sold

1 / 5

executives and directors

Last open-market buy

Dec 2025

Dec 26, 2025

Get an email when MNPR's executives or directors buy, or make a large sale outside a plan.

Trades · last 2 years

Date	Insider	Trade	Shares	Price	Value	Of their stake	Filing
Nov 2 – 4	Kim R Tsuchimoto Director	Sold10b5-1 plan 4 parts	4,090	$70.92 average	290K	26%	Form 4
Nov 2	Raymond Anderson Director	Sold10b5-1 plan 4 parts	3,142	$68.35 average	215K	37%	Form 4
Oct 1	Christopher M Starr Director	Sold10b5-1 plan 3 parts	8,400	$78.50 average	659K	36%	Form 4
Sep 24	Chandler Robinson Chief Executive Officer	Sold10b5-1 plan 4 parts	29,056	$88.00 average	$2.56M	15%	Form 4
Aug 26	Kim R Tsuchimoto Director	Sold10b5-1 plan 6 parts	4,090	$111.39 average	456K	26%	Form 4
Aug 26	Patrice Rioux Other	Sold10b5-1 plan	1	$111.26	$111	<0.1%	Form 4
Aug 25	Raymond Anderson Director	Sold10b5-1 plan 3 parts	3,142	$111.98 average	352K	37%	Form 4
Dec 26, 2025	Quan Anh Vu Chief Financial Officer	Bought	1,500	$69.95	105K	New	Form 4
Dec 18, 2025	Arthur J Klausner Director	SoldNo plan 2 parts	5,121	$67.15 average	344K	37%	Form 4
Sep 24, 2025	Tactic Pharma LLC Chief Executive Officer	SoldNo plan	550,229	$63.61	$35M	67%	Form 4
Jul 14, 2025	Kim R Tsuchimoto Director	SoldNo plan	8,904	$40.00	356K	44%	Form 4
Jul 14, 2025	Christopher M Starr Director	SoldNo plan	16,800	$40.00	672K	53%	Form 4
Jul 14, 2025	Chandler Robinson Chief Executive Officer	SoldNo plan	16,800	$40.00	672K	1.8%	Form 4
Apr 2, 2025	Michael J Brown Other	SoldNo plan	33,334	$35.00	$1.17M	3.9%	Form 4

Nov 2 – 410b5-1 plan
Kim R Tsuchimoto
Director · sold 4,090 at avg $70.92
290K
26% of stake
Nov 210b5-1 plan
Raymond Anderson
Director · sold 3,142 at avg $68.35
215K
37% of stake
Oct 110b5-1 plan
Christopher M Starr
Director · sold 8,400 at avg $78.50
659K
36% of stake
Sep 2410b5-1 plan
Chandler Robinson
Chief Executive Officer · sold 29,056 at avg $88.00
$2.56M
15% of stake
Aug 2610b5-1 plan
Kim R Tsuchimoto
Director · sold 4,090 at avg $111.39
456K
26% of stake
Aug 2610b5-1 plan
Patrice Rioux
Other · sold 1 at $111.26
$111
<0.1% of stake
Aug 2510b5-1 plan
Raymond Anderson
Director · sold 3,142 at avg $111.98
352K
37% of stake
Dec 26, 2025
Quan Anh Vu
Chief Financial Officer · bought 1,500 at $69.95
105K
New position
Dec 18, 2025No plan
Arthur J Klausner
Director · sold 5,121 at avg $67.15
344K
37% of stake
Sep 24, 2025No plan
Tactic Pharma LLC
Chief Executive Officer · sold 550,229 at $63.61
$35M
67% of stake
Jul 14, 2025No plan
Kim R Tsuchimoto
Director · sold 8,904 at $40.00
356K
44% of stake
Jul 14, 2025No plan
Christopher M Starr
Director · sold 16,800 at $40.00
672K
53% of stake
Jul 14, 2025No plan
Chandler Robinson
Chief Executive Officer · sold 16,800 at $40.00
672K
1.8% of stake
Apr 2, 2025No plan
Michael J Brown
Other · sold 33,334 at $35.00
$1.17M
3.9% of stake

How to read this. Insiders sell for many reasons: taxes, diversifying, a house. Open-market buys are rarer and say more. A 10b5-1 plan is a trading schedule set up months in advance, so those sales were not timed on news. Large holders (funds and 10% owners) are listed under Everything but not counted as insiders. If you own or watch MNPR, we send a push when an executive buys or makes a large sale outside a plan.

Source: SEC Form 4 filings, filed within two business days of each trade and checked for new ones every hour.

Peers

Pharmaceutical Preparations · Pick stocks to compare with MNPR

CompareIntrinsic value

DERMJourney Medical Corp

$4.73+1.94%25

SPROSpero Therapeutics Inc.

$1.07+2.88%63

ABUSArbutus Biopharma Corporation

$4.06+4.64%60

LGVNLongeveron Inc.

$1.78+0.00%10

INOInovio Pharmaceuticals, Inc.

$1.62-2.41%10

SPRBSpruce Biosciences Inc.

$46.61+8.88%10

ALTAltimmune, Inc.

$2.12+3.92%10

AZTRAzitra Inc.

$0.82-7.69%19

Held by ETFs

MNPR is in 10 US ETFs. The largest of them, with MNPR's weight in each:

Spot a number that looks wrong? Check it in MNPR's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing MNPR

Create a free account and get 14 days of Premium: every stock and every tool.

Unlimited stocksQuality, fair value and dividends for 10,000+ stocks
Stock screenerFilter on quality, valuation and dividend safety
Portfolio trackerReal return, dividend calendar and portfolio quality
Editable DCFChange the assumptions and watch fair value move
Compare side by sideUp to 10 stocks in one table
Unlimited alertsPrice, P/E, Quality Score and yield

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.